Description of Medical ServiceBrexucabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical ConditionAcute lymphoblastic leukaemia is a blood cancer that appears suddenly and grows rapidly. It starts when immature white blood cells called blasts become cancerous.
Reason for ApplicationHighly Specialised Therapy - National Health Reform Agreement
Medical Service TypeTherapeutic technology
Previous Application Number/sNot Applicable
Application FormApplication Form (PDF 1044 KB)
Application Form (Word 787 KB)
Consultation SurveyConsultation Survey (PDF 323 KB)
Consultation Survey (Word 72 KB)
Expedited – Bypassing PASC
MSAC consultation input must be received by no later than Friday, 7 October 2022 for it to be considered by MSAC at its November 2022 meeting.
For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process